AGC Biologics Named Manufacturing Company of the Year by American Business Awards


Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites 

AGC Biologics Honored as a Top 10 Company for Pharma Quality Assurance

AGC Biologics today announced it has been named a Top 10 Top Quality Assurance Services provider by Pharma Tech Outlook Europe.

Tony Fraij Joins Colorado BioScience Association Board of Directors

AGC Biologics today announced the appointment of Tony Fraij, AGC Biologics’ Longmont General Manager, to the Colorado BioScience Association (CBSA) Board of Directors.

AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus

AGC Biologics today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in the third quarter of 2022, complement the campus’ adherent viral vector and cell therapy offerings – enabling AGC Biologics to provide an in-depth variety of end-to-end cell and gene therapy services at this site.

AGC Biologics Provides Aid to Ukraine


AGC Biologics is deeply concerned and grieved about the situation in Ukraine. We sincerely hope that peaceful life will return to everyone as soon as possible. We also stand in partnership with our parent company, AGC Inc., in providing support for the safety and wellbeing of our Ukrainian colleagues and their families.   

Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate


AGC Biologics is producing vaccine materials for early-stage product trials at its Heidelberg facilities

AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material

News, Company News, Partnership

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.

AGC Biologics Names Regina Choi-Rivera General Manager of Boulder Facility

News, Company News

AGC Biologics today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations.

AGC Biologics Appoints Whitney Sandberg as the new Vice President of Quality for its Colorado Facilities

Company News

AGC Biologics today announced Whitney Sandberg has been appointed as the company’s Vice President for Quality in Colorado. In this position she will have executive oversight for quality operations at the company’s two facilities in the state, located in Boulder and Longmont. Both facilities provide AGC Biologics critical resources for serving its global clientele, and Sandberg’s expertise will ensure each location produces products of the highest quality that meet global GMP requirements and industry expectations.

I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project


AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.

Follow Us
Join us on LinkedIn Follow us on Twitter